Abstract

Bitter taste receptors (TAS2Rs), a subfamily of G-protein coupled receptors (GPCRs) expressed orally and extraorally, elicit signaling in response to a large set of tastants. Among 25 functional TAS2Rs encoded in the human genome, TAS2R14 is the most promiscuous, and responds to hundreds of chemically diverse ligands. Here we present the cryo–electron microscopy (cryo-EM) structure of the human TAS2R14 in complex with its signaling partner gustducin, and bound to flufenamic acid (FFA), a clinically approved nonsteroidal anti-inflammatory drug. The structure reveals an unusual binding mode, where two copies of FFA are bound at distinct pockets: one at the canonical receptor site within the trans-membrane bundle, and the other in the intracellular facet, bridging the receptor with gustducin. Together with a pocket-specific BRET-based ligand binding assay, these results illuminate bitter taste signaling and provide tools for a site-targeted compound design.

Bitter taste receptors (TAS2Rs) are a subfamily of G-protein coupled receptors (GPCRs). Here, the authors report a cryo-EM structure of the human TAS2R14 in complex with its signaling partner gustducin, and bound to an anti-inflammatory drug flufenamic acid (FFA).

Details

Title
A bitter anti-inflammatory drug binds at two distinct sites of a human bitter taste GPCR
Author
Peri, Lior 1   VIAFID ORCID Logo  ; Matzov, Donna 2 ; Huxley, Dominic R. 3 ; Rainish, Alon 1 ; Fierro, Fabrizio 1   VIAFID ORCID Logo  ; Sapir, Liel 4   VIAFID ORCID Logo  ; Pfeiffer, Tara 5   VIAFID ORCID Logo  ; Waterloo, Lukas 5   VIAFID ORCID Logo  ; Hübner, Harald 5   VIAFID ORCID Logo  ; Peleg, Yoav 6 ; Gmeiner, Peter 7   VIAFID ORCID Logo  ; McCormick, Peter J. 8 ; Weikert, Dorothee 7   VIAFID ORCID Logo  ; Niv, Masha Y. 1   VIAFID ORCID Logo  ; Shalev-Benami, Moran 2   VIAFID ORCID Logo 

 The Hebrew University of Jerusalem, The Institute of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538); The Hebrew University, The Fritz Haber Research Center, and the Harvey M. Kruger Center for Nanoscience & Nanotechnology, Institute of Chemistry, Jerusalem, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538) 
 Weizmann Institute of Science, Department of Chemical and Structural Biology, Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563) 
 Charterhouse Square, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary, University of London, London, UK (GRID:grid.4464.2) (ISNI:0000 0001 2161 2573) 
 The Hebrew University of Jerusalem, The Institute of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538); The Hebrew University, The Fritz Haber Research Center, and the Harvey M. Kruger Center for Nanoscience & Nanotechnology, Institute of Chemistry, Jerusalem, Israel (GRID:grid.9619.7) (ISNI:0000 0004 1937 0538); Bar-Ilan University, Department of Chemistry, Ramat-Gan, Israel (GRID:grid.22098.31) (ISNI:0000 0004 1937 0503) 
 Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Chemistry and Pharmacy, Medicinal Chemistry, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311) 
 Weizmann Institute of Science, Structural Proteomics Unit (SPU), Life Sciences Core Facilities (LSCF), Rehovot, Israel (GRID:grid.13992.30) (ISNI:0000 0004 0604 7563) 
 Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Chemistry and Pharmacy, Medicinal Chemistry, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); Friedrich-Alexander-Universität Erlangen-Nürnberg, FAUNeW – Research Center New Bioactive Compounds, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311) 
 Charterhouse Square, Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary, University of London, London, UK (GRID:grid.4464.2) (ISNI:0000 0001 2161 2573); University of Liverpool, Department of Pharmacology and Therapeutics, Faculty of Health and Life Sciences, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470) 
Pages
9991
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3129871213
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.